Diabetic nephropathy among Mexican Americans

Subrata Debnath1, Farook Thameem1, Tahira Alves1,2, Jacqueline Nolen1, Hania Al-Shahrouri1,2, Shweta Bansal1, Hanna E. Abboud1,2 and Paolo Fanti1,2

1Division of Nephrology, University of Texas Health Science Center at San Antonio and 2Renal Section, Audie L. Murphy VA Hospital, San Antonio, TX, USA

Abstract. The incidence of diabetic nephropathy (DN) is growing rapidly worldwide as a consequence of the rising prevalence of Type 2 diabetes mellitus (T2DM). Among U.S. ethnic groups, Mexican Americans have a disproportionately high incidence and prevalence of DN and associated end-stage renal disease (ESRD). In communities bordering Mexico, as many as 90% of Mexican American patients with ESRD also suffer from T2DM compared to only 50% of non-Hispanic Whites (NHW). Both socio-economic factors and genetic predisposition appear to have a strong influence on this association. In addition, certain pathogenetic and clinical features of T2DM and DN are different in Mexican Americans compared to NHW, raising questions as to whether the diagnostic and treatment strategies that are standard practice in the NHW patient population may not be applicable in Mexican Americans. This article reviews the epidemiology of DN in Mexican Americans, describes the pathophysiology and associated risk factors, and identifies gaps in our knowledge and understanding that needs to be addressed by future investigations.

Introduction

Mexican Americans are a unique racial mix of American Indians and Europeans, especially Spaniards [1]; they represent 2/3 of Hispanic Americans and are the largest and fastest growing ethnic minority in the United States [2, 3]. Despite objective difficulties in discriminating between Mexican Americans and other Hispanic American subgroups based on current official definitions [4, 5] and medical literature, the available data suggest that Mexican Americans are at a greater risk than other subgroups for developing T2DM and its micro- and macrovascular complications including nephropathy (T2DN), retinopathy, neuropathy and cardiovascular disease [6]. Therefore, it is not surprising that the health of Mexican Americans is of increasing concern to U.S. health-care providers, researchers, and policy makers. This paper reviews the current knowledge and understanding of T2DN in Mexican Americans and attempts to identify the major knowledge gaps and disease management deficiencies specific to the Mexican American population. The hope is that this information will serve as a foundation upon which future research and clinical initiatives can be based.

Methods

We searched the electronic databases PubMed, EMBASE, SCOPUS, Web of Science and CINAHL for original articles based on the following inclusion criteria: publication in the English literature after 1970, full report of original cross-sectional, prospective, or observational human studies, evaluation of T2DM and/or T2DN, and analysis of incidence, prevalence, progression and/or complications. We identified articles of interest based on the following key words: adult-onset diabetes mellitus, T2DM, maturity onset diabetes mellitus, non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, metabolic syndrome, diabetic nephropathy, chronic kidney disease, diabetic kidney disease, uremia, renal failure, end-stage renal disease (ESRD), hemodialysis, minorities, health disparities, Hispanics, Mexican Americans, Latinos, obesity, central obesity, body mass index (BMI), socioeconomic status, acculturation, genetics, migration, diet, nutrition, lifestyle risk factors, environmental risk factors, incidence, prevalence, prevention, etiology, complications, progression, treatment, intervention, management, alternative
Diabetic kidney disease in Mexican Americans

In addition, we screened relevant citations from review articles and trials to identify articles that were not found through the database searches. We methodically identified studies that focused on Mexican Americans or Hispanics/Latinos and that targeted geographic areas where Mexican Americans are clustered including West (California) and Southwest (Texas). Studies on NHWs were also analyzed for comparison. One objective limitation of this literature search and analysis originates from the lack of consensus about the definition of Mexican Americans in health-related research. For example, the Hispanic Health and Nutrition Examination Survey (HHANES) [5] defined Hispanic subgroups based on self-reported national origin or ancestry, while Hazauda et al. [6] emphasized the importance of parental surnames as indication of Mexican-American ethnicity. With few exceptions, e.g., the San Antonio Family Diabetes/Gallbladder Study (SAFDGS) and the San Antonio Family Heart Study (SAFHS), most of the reviewed studies used self-reported ethnicity to identify Mexican Americans.

T2DN among Mexican Americans

Hispanic Americans are the ethnicity with the highest estimated lifetime risk of diabetes in the US [7]. Further, surveys conducted in the 1990’s demonstrated that both the incidence and prevalence of T2DM were at least 2-fold higher in the Hispanic subgroup of Mexican Americans than in NHW and were substantially higher in Mexican Americans than in any other Hispanic subgroup except for Puerto Ricans [8, 9, 10, 11, 12, 13, 14]. Not surprisingly, a similar incidence and prevalence of T2DN was also observed in this population [6, 15, 16, 17]. For example, in the San Antonio Heart Study (SAHS), micro- and macroalbuminuria were observed in 26% and 11%, respectively, of Mexican Americans compared to only 9% and 5% of NHWs [16]. This heightened susceptibility of Mexican Americans to T2DM and T2DN is the object of ongoing study and debate and is the focus of this paper.

The American Indian genetic pool is believed to contribute substantially to the high rates of T2DM and T2DN among Mexican Americans. Indeed, T2DM and T2DN occur with extremely high frequency among American Indians, as extensively documented among the Pima Indians who presumably have close to 100% native American genes [18]. The rate of T2DM in Mexican Americans has been suggested to parallel the percent of gene pool derived from the American Indian population [19]. A prospective study of Pima Indians with T2DM also demonstrated an exceptionally high percent of patients (37%) who progressed from micro- to macroalbuminuria over a 4-year period [20]. In the same population, a 20-year history of T2DM was associated with a 50% cumulative incidence of macroalbuminuria [21]. The latter, in turn, was associated with a 42-fold higher progression toward ESRD, confirming the role of albuminuria as an ominous prognostic marker of end organ failure in this ethnic group [21].

Interestingly, more recent surveys contradict the above observations by reporting a lower prevalence of chronic kidney disease (CKD) in Mexican Americans than in NHWs [11, 22, 23, 24, 25]. The authors of these latter studies offer several possible explanations for this incongruence including race- and ethnicity-based differences in the 1) accuracy of the equations used to estimate glomerular filtration rate (eGFR), 2) diagnostic tests for microalbuminuria, 3) progression rate of CKD, 4) death rate prior to reaching ESRD, and 5) access to health care [23, 25, 26]. To our knowledge, the only study that has attempted to further clarify this issue was a retrospective observational study that compared random samples of Mexican American, African American and NHW patients with ESRD due to Type II DM (ESRD-DM). In this study, the rate of progression of renal disease was faster in Mexican Americans than in the other ethnic groups and was shown to be independent of blood pressure and glycemic control [27]. Based on these findings the authors concluded that other yet to be identified risk factors for ESRD-DM beyond the traditional risk factors of blood pressure and glycemic control are present in the Mexican American population. If confirmed to be true this could have significant implications for nephrologists and other health care professionals who care for the Mexican American population since it would set Mexican Americans apart from other patient populations in whom glycemic and
blood pressure control are important determinants of the incidence and rate of progression of T2DN [28, 29]. Finally, further complicating our understanding of the relationship between T2DM, T2DN, and ESRD-DM in the Mexican American population is the recently emphasized inaccuracy of albuminuria as a biomarker of CKD; in fact, a relatively large fraction of T2DM patients, including Mexican Americans, present with normoalbuminuria despite an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m² [30, 31, 32, 33]. This latter observation implicates the existence of other pathogenetic expressions of T2DN which possibly may be dependent in part on genetic and lifestyle factors.

ESRD among Hispanic Americans and Mexican Americans with T2DM

National statistics regarding ESRD in Hispanic Americans became available after 1994 when Medicare and Medicaid introduced an ethnicity query on the 2,728 ESRD Registration form. Based on data from the United States Renal Data System (USRDS), the prevalence of ESRD-DM has been 2-fold higher in Hispanics than in non-Hispanics since 2001 [34, 35]. During this time period, the incidence rate has been relatively stable with 311 – 326 new cases/million Hispanics, while the prevalence rate has increased by 13%, from 1,141 to 1,306 cases/million, probably as a result of improved survival with renal replacement therapy [13, 14].

Unfortunately, prospective data of comparable quality are not available in the Mexican American subgroup of Hispanic Americans. However, an epidemiological survey conducted in Southern-Central Texas in the 1980’s found a 4-fold to greater than 9-fold higher incidence of ESRD in Hispanics – almost all Mexican Americans – than in NHW [15]. In 1995, a combined survey of the San Antonio and Dallas areas confirmed that an impressive 93% of Mexican Americans with ESRD also suffered from T2DM [36] compared to a 40% prevalence of T2DM in the overall ESRD patient population in the U.S. Between 1996 and 2006, the Mexican Americans experienced a faster incident growth of ESRD compared to African Americans and Native Indians [35, 37]. Another interesting observation is that the distribution of ESRD-DM by U.S. state correlates relatively well with that of Mexican Americans. For example, in 2007 the incidence of ESRD-DM was highest (183 – 225 cases/million population) in California, Arizona, West Virginia, New Mexico, Hawaii, and Texas, i.e. mostly states with large Mexican American populations, while it was lowest (83 – 110 cases/million population) in Wyoming, Vermont, Montana, New Hampshire, Maine, and Oregon, i.e. states with low Mexican American population [38]. Although these data are obviously biased by lack of control for recent immigration and naturalization trends in the U.S. they suggest a strong association between ethnicity and the incidence of ESRD-DM in the U.S. [34, 35] and they allow us to predict a significant impact of Mexican Americans on the future incidence of ESRD in the U.S.

In addition, Hispanics with ESRD have also been estimated to have a 20 – 30% lower mortality risk than their NHW counterparts [39, 40]. The survival advantage of Hispanics compared to NHWs has been observed repeatedly despite the higher prevalence of T2DM in this patient population, a phenomenon often referred to as the “Hispanic Paradox” [39, 41, 42]. Further, in a recent subgroup analysis, Mexican and Cuban Americans with ESRD were also shown to have better survival compared to Puerto Ricans and non-Hispanics [42]. The survival advantages in both Hispanics and the Hispanic subgroup of Mexican Americans have been attributed to age, BMI, serum albumin, blood hemoglobin concentrations, and hemodialysis adequacy [39, 41, 42]. For example, high BMI in Hispanic ESRD patients is associated with “reverse epidemiology” which confers a benefit toward survival [43, 44].

Genetic predisposition to T2DN among Mexican Americans with T2DM

Epidemiological studies strongly imply genetics as a major contributor to the development, progression and heritability of T2DN as of T2DM [45]. Genetic studies in Mexican Americans support this as demonstrated by the finding of familial clustering of
T2DN and related phenotypes in this population. However, despite mounting appreciation for the influence of genetic variation on the risk for development of chronic diseases, the specific gene(s) involved in the susceptibility to T2DN and related phenotypes remains elusive [46, 47]. T2DN susceptibility genes have been investigated in Mexican Americans as part of several recent large studies, including the Family Investigation of Nephropathy and Diabetes (FIND) [48], the SAFDGS [49], the SAFHS [50], and the National Health and Nutrition Examination Survey (NHANES) [51]. Linkage and biological candidate gene analyses, mapping by admixture linkage disequilibrium (MALD) and genome-wide association studies are some of the strategies that have been used in these studies to identify susceptibility loci and genes for T2DN and related phenotypes.

In Mexican Americans recruited for FIND, genome-wide linkage analysis reported an association between mutations of certain chromosomal regions with the presence of T2DN (9q33), albuminuria (9q31) and GFR (1q43, 2p13, 7q36.1, 8q21.3, 18q23) [52, 53]. In SAFDGS, the same analytical methodology suggested an association between albuminuria and variation in the GABRB3-flanking region on chromosome 15q12 [54] and between GFR and the D2S427-flanking region on chromosome 2q36. However, within the GABRB3-flanking region genetic variations of the positional candidate genes tight-junction protein-1 (TJP1) and gremlin-1 (GREM1) failed to show evidence of an association with albuminuria [55, 140].

A quantitative trait linkage scan of subjects recruited for SAFHS showed the strongest association of albuminuria, serum creatinine and GFR with variations in chromosome regions 20q12 and 9q21, respectively [57, 58]. In the same cohort, GFR and serum creatinine also displayed somewhat weaker associations with the 2p25 region [58].

In addition, genes involved in the regulation of blood pressure, endothelial biology and redox functions have also been investigated in Mexican Americans as possible candidate genes for susceptibility to T2DN and related phenotypes. Unfortunately, genetic variations that have previously yielded promising results including those of endothelial nitric oxide synthase (eNOS), paraoxonase 2 (PON2) and components of the renin-angiotensin system failed to demonstrate any strong associations with albuminuria or GFR in the SAFDGS and SAFHS cohorts [56]. Chu et al. [59] also did not find any association between the e2/e4 alleles of APOE and GFR in 1,656 Mexican Americans from NHANES III. Use of MALD in Mexican Americans in the FIND study led to the novel observation of an association with the genetic variants of hemicentin 1 but failed to confirm the previously reported association of T2DN with carnosine dipeptidase 1 (CNDP1) and engulfment and cell motility 1 (ELMO1) [60].

In summary, the identification of several candidate gene loci has not yet resulted in the discovery of major susceptibility gene for T2DN in Mexican Americans. Still, recent identification by linkage and candidate gene analysis of calpain 10 (CAPN10) and transcription factor 7-like 2 (TCF7L2) as susceptibility genes for T2DM in Mexican Americans offers hope for the future discovery of T2DN-specific genetic traits in this same population [61, 62, 63, 64, 65, 66].

Collectively, these analytical tools may assist in accelerating the identification of gene variations that may contribute to the development and progression of T2DN in Mexican Americans and possibly other ethnic populations. In addition, ongoing discovery of proteins and other signaling pathways that are functionally relevant to the pathophysiology of T2DN will provide opportunities for further testing of new genetic variations.

Other risk factors, prevention and treatment of T2DN among Mexican Americans with T2DM

Current standard practice is to manage T2DM and T2DN in Mexican Americans using the same basic principles of risk, prevention, and treatment that are applied to the general population. However, as discussed in this section, evidence-based data from prospective clinical trials underscore the need for more studies that specifically target ethno-specific approaches to the care of T2DM and T2DN within the Mexican American population.
**Hypertension**

The NHANES have consistently reported lower prevalence of hypertension in the general and T2DM Mexican American population than in their NHW and African American counterparts [17, 67, 68, 69, 70, 71, 72]. This phenotypic trait can possibly be explained by the previously mentioned contribution of American Indians to the Mexican Americans genetic pool and by the observation that American Indians, specifically the Pima Indians, do not experience the same positive correlation of blood pressure with insulin resistance and T2DM that is present in NHWs [73, 74]. Other plausible explanations for the lower incidence of hypertension in Mexican Americans with T2DM may be due to differences in disease diagnosis, awareness, treatments, and adherence to therapy among Mexican Americans compared to African Americans or NHWs [17, 70, 72, 75, 76, 77]. Interestingly, recent data from the Hispanic-Chronic Renal Insufficiency Cohort study seem at odds with the above evidence in the general diabetic population, since they suggest that once CKD is established, the prevalence of hypertension becomes higher in Mexican Americans with CKD than in NHW with CKD, even though this study did not stratify for diabetes status [78]. With regard to treatments, it is interesting that antihypertensive medications particularly well-suited to protect against the development and progression of T2DN, including the angiotensin receptor blockers (ARBs) and angiotensin converting enzyme inhibitors (ACE-I) [79, 80, 81], are not as commonly prescribed in Mexican Americans as in other ethnic groups with diabetes [82, 83, 84]. In addition, the efficacy of these classes of medications in Mexican Americans compared to other ethnicities has recently been questioned. In a post-hoc analysis of an international study, the ARB losartan was shown to provide weaker protection from progression to ESRD in Hispanics compared to NHWs, African Americans and Asians although the effect on proteinuria was comparable among groups [85]. Analysis by the Agency for Healthcare Research and Quality [86] highlights the scarcity of comparative information on benefits and harms of ACE-I and ARBs in minority populations including Mexican Americans. More research is needed that aims to determine the benefits of these agents among often understudied minority populations.

**Hyperglycemia**

Several observational and interventional studies across ethnic and racial groups, including the Diabetes Control and Complications Trial (DCCT), the United Kingdom Prospective Diabetes Study (UKPDS), and the Steno-2 study, indicate that optimal glycemic control, independent of blood pressure control, prevents or reverses the early manifestations of nephropathy in patients with T2DM [87, 88, 89, 90, 91, 92]. Unfortunately, cross-sectional and prospective studies of both incidental and established T2DM have consistently shown that Mexican Americans experience inferior quality of care and glycemic control compared to other ethnic groups [17, 71, 93, 94, 95, 96, 97, 98, 99]. For example, between 1988 and 2002, HbA1c was found to be greater than 9.5% in 22% of Mexican Americans compared to 16% of NHWs with T2DM. In addition, there was no evidence of improvement in this disparity during long-term follow-up [100, 101]. Furthermore, it was observed that only 28% of Mexican Americans self-monitor blood glucose as compared to 44% of NHWs and 36% of African Americans, a practice associated with a healthier lifestyle in patients with T2DM, particularly those not using insulin [96].

**Dyslipidemia**

Elevated serum cholesterol has been shown to predict the development of albuminuria in patients with T2DM [102], although it is unknown whether this finding holds true in Mexican Americans. In addition, the prevalence of dyslipidemia in the Hispanic population is uncertain. In one report, the presence of hypercholesterolemia and hypertriglyceridemia were 36% and 42% less common, respectively, in Hispanics compared to NHWs with T2DM. More recently, a multi-ethnic study of atherosclerosis reported comparable prevalence of dyslipidemia in Hispanics and NHWs, although the Hispanic subjects were less likely to be appropriately treated [103].
Compared to NHWs, it has also been demonstrated that Mexican Americans are less aware of suffering from dyslipidemia (55% vs. 33%) and are less likely to be treated (30% vs. 14%) [97]. Similar observations have also been made when comparing Mexican Americans and NHWs regarding T2DM. In addition, Mexican Americans with and without T2DM are approximately 30% less likely than NHWs to be diagnosed and treated with diet or medications for their dyslipidemia [17]. Unfortunately, there are no data currently available describing the prevalence and pathogenetic significance of dyslipidemia in Mexican Americans with T2DN.

Obesity

A causal role of obesity in the pathogenesis of T2DN has been hypothesized [97] although the available clinical studies are inconsistent. A European longitudinal study found no independent association between obesity and T2DN [105]. However, more recently the Look AHEAD study reported a positive correlation between abdominal obesity but not total body fat and albuminuria in T2DM subjects [106]. Furthermore, a meta-analysis has concluded that a reduction in body weight leads to lower proteinuria and microalbuminuria in T2DM, although it is not known if this translates into a reduction in the incidence of ESRD in clinical practice [107].

Despite a very high prevalence of obesity among Mexican Americans, we are not aware of any analysis that specifically addresses the association between obesity and T2DN in this population. It has however been shown that age, duration of diabetes, retinopathy, hypertension, and cardiovascular disease are among the most significant predictors for the development of nephropathy in obese Mexican Americans with T2DM [108].

Life-style and socio-economic status

Risk factors for insulin resistance that depend on life-style and socio-economic status are highly prevalent in Mexican Americans, including accumulation of abdominal visceral fat with central obesity [109, 110], excess alcohol consumption, lack of physical activity [111], and lower education level [69]. This is relevant since insulin resistance is the major metabolic abnormality in T2DM and the prevalence of risk factors for insulin resistance in Mexican Americans may be contributing significantly to the excess T2DM in this population [112, 113, 114, 115, 116, 117]. In a recent cross-sectional analysis, physical activity correlated with both glomerular filtration rate (GFR) and proteinuria in NHWs and with GFR in Mexican Americans [118]. Additionally, erratic management of T2DM, mostly a consequence of socio-economic and access barriers, has been correlated with an increased risk of progression of kidney disease in elderly Mexican Americans [119].

Alternative therapy for T2DN

Use of complementary and alternative medicine (CAM) for T2DM and T2DN is a very prevalent practice among Mexican Americans, presumably as a consequence of their strong ties to their culture, relatively low socioeconomic status, and inadequate access to conventional medical care. Small studies have shown that *nopal* (prickly pear cactus) and *aloe vera* are widely used as CAM by Mexican Americans with T2DM [120, 121, 122, 123]. Poss et al. [124] also reported that *Te Diabetil*, a combination of several herbs, is frequently used by Mexican Americans for the management of T2DM along with prescribed allopathic medicine. Unfortunately, the National Health Interview Survey (NHIS), a large cross-sectional survey on health status and use of CAM in adults with diabetes, and other studies based on this survey [125, 126, 127] did not specifically addressed the use of CAM in Mexican Americans. In addition, none of the above studies specifically addressed the use of any of these CAM remedies for the treatment of T2DN. Markell [128] suggests the potential benefits of complementary medicines for CKD, however, the etiology of CKD is not specified and therefore the relevance to T2DM is not known. In summary, the current knowledge regarding these therapies is abysmally insufficient to determine efficacy and one must remain well aware that, contrary to many consumer expectations, CAM
remedies may actually be harmful. On the other hand, it is possible some of these therapies may actually provide not yet recognized modalities of treatment that are useful especially for aspects of the disease that are not adequately addressed by current conventional therapy. For example, excessive oxidative stress has been identified as a possible contributor to the pathogenesis of many forms of disease including both T2DM and CKD [129, 130, 131, 132]. Although conventional Western medicine does not currently offer interventions that directly address oxidative stress and its associated redox defects it is possible that herbal remedies, supplements, or a group of compounds referred to as nutraceuticals that contain antioxidants may correct these defects in T2DN and other forms of CKD. At present this hypothesis is untested and requires further evaluation in both the preclinical and clinical research settings.

Prevention of T2DN

Identification of subjects at risk for T2DM, or with established pre-diabetes, early T2DM, or microalbuminuria are self-evident important steps for prevention of both T2DM and T2DN [133, 134]. Unfortunately, despite particularly long duration of T2DM in Mexican Americans, diagnosis tends to be made late in this population [135, 136]. Culturally sensitive efforts are underway to mitigate T2DM among Latinos as described by the Lawrence Latino Diabetes Prevention Project [137] and the La Diabetes y La Unión Familiar [138], among others. We are not aware of any programs to reduce or prevent the burden of T2DN among Mexican Americans specifically [139]. We submit, however, that a renewed effort from primary and specialty health care providers to educate patients about healthy lifestyle, to diagnose in timely manner T2DM and microalbuminuria and to refer early to a nephrologist would be steps in the right direction. This approach should consider and respect Mexican American culture and values including language, religion, health beliefs, and diet, as well as the community context – extended family and support systems – and the challenges of acculturation.

Conclusions

T2DN is highly prevalent among Mexican Americans. The medical impact of this disease is extensive and is of concern to health care providers and the overall U.S. health care system, especially in consideration of the rapid demographic growth of Mexican Americans in the U.S. Many modifiable and non-modifiable risk factors of T2DN have been identified or proposed in this vulnerable population. T2DM and hypertension are paramount among the modifiable biological risk factors. In addition, low formal education level, lack of health insurance and limited access to health care have been identified as modifiable socioeconomic factors that, if left unchallenged, will interfere with any attempt aimed at correcting the biological predictors.

This review highlights some important differences in the incidence, prevalence and risk of T2DN in the Mexican American population. The available evidence suggests that unique social, clinical and pathogenetic factors bear on the incidence and prevalence of T2DN among Mexican Americans. Clinical management of T2DN in this ethnic group may therefore benefit from direct confrontation and resolution of these ethnicity-specific differences. Further, although the identification of gene variations that predispose Mexican Americans to T2DN has progressed slowly during the last 2 decades, this effort is far from complete and should continue.

We acknowledge the need for further studies in this patient population. We anticipate that future studies will include this high-risk population so that the natural history of T2DN can be further elucidated and that scientific evidence can be obtained that will assist in the development of future recommendations for screening, prevention, and treatment.

Acknowledgments

This work was supported by grants to Subrata Debnath (AHA#0525206Y), Farook Thameem (American Society of Nephrology), Paolo Fanti (NIH#AT004490 and VA#1I01CX000264), and Hanna Abboud (NIH# DK-R01-078971 and VA Merit Review).
References

[1] Tiwari SC. Studies of crossing between Indians and Europeans. Ann Hum Genet. 1963; 26: 219-227. doi:10.1111/j.1469-1809.1963.tb01978.x PubMed

[2] U.S. Census Bureau. Hispanic Heritage Month 2009, in Facts for Features, U.S.C.B. News, Editor. 2009: Washington, D.C.

[3] Palmer Alves, Lewis J. Racial differences in chronic kidney disease (CKD) and end-stage renal disease (ESRD) in the United States: a social and economic dilemma. Clin Nephrol. 2010; 74 (Suppl 1): S72-S77 PubMed

[4] Office of Management and Budget. Revisions to the Standards for the Classification of Federal Data on Race and Ethnicity. 1997 Federal Register Notice, October 30, 1997 cited; Available from: http://www.whitehouse.gov/omb/fedreg_1997standards/

[5] Office of Extramural Research. M.D. studies of the elderly. Am J Public Health. 1999; 89: 1213-1220. PubMed

[6] Patterson KM. The Diabetes in Hispanic Americans, U.S. D.O.H.a.H. Services, Editor. The National Diabetes Information Clearinghouse (NDIC); 1995. p. 631-660.

[7] Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA. 2003; 290: 1884-1890. doi:10.1001/jama.290.14.1884 PubMed

[8] Haffner SM, Hazuda HP, Mitchell BD, Patterson JK, Stern MP. Increased incidence of Type II diabetes mellitus in Mexican Americans. Diabetes Care. 1991; 14: 102-108. doi:10.2337/diabetes.33.1.86 PubMed

[9] Flegal KM, Ezzati TM, Harris MI, et al. Prevalence of diabetes in Mexican Americans, Cubans, and Puerto Ricans from the Hispanic Health and Nutrition Examination Survey, 1982-1984, in Diabetes Care. 1991. p. 628-638.

[10] Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer HM, Byrd-Holt DD. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998; 21: 518-524. doi:10.2337/diabetes.21.4.518 PubMed

[11] Black SA, Ray LA, Markides KS. The prevalence and health burden of self-reported diabetes in older Mexican Americans: findings from the Hispanic established populations for epidemiologic studies of the elderly. Am J Public Health. 1999; 89: 546-552. doi:10.2105/AJPH.89.4.546 PubMed

[12] Mitchell BD, Stern MP, Haffner SM, Hazuda HP, Patterson JK. Risk factors for cardiovascular mortality in Mexican Americans and non-Hispanic whites. San Antonio Heart Study. Am J Epidemiol. 1991; 133: 423-433. PubMed

[13] Hamman RF, Marshall JA, Baxter J, Kahn LB, Mayer EJ, Orleans M, Murphy JR, Lezotte DC. Methods and prevalence of non-insulin-dependent diabetes mellitus in a biethnic Colorado population. The San Luis Valley Diabetes Study. Am J Epidemiol. 1989; 129: 295-311 PubMed

[14] Lindeman RD, Romero LJ, Hundley R, Allen AS, Liang HC, Baumgartner RN, Koehler KM, Schade DS, Giurry PJ. Prevalences of type 2 diabetes, the insulin resistance syndrome, and coronary heart disease in an elderly, biethnic population. Diabetes Care. 1998; 21: 959-966. doi:10.2337/diabetes.21.6.959 PubMed

[15] Pugh JA, Stern MP, Haffner SM, Efier CW, Zapata M. Excess incidence of treatment of end-stage renal disease in Mexican Americans. Am J Epidemiol. 1988; 127: 135-144. PubMed

[16] Haffner SM, Mitchell BD, Pugh JA, Stern MP, Kozlowski MK, Hazuda HP, Patterson JK, Klein R. Proteinuria in Mexican Americans and non-Hispanic whites with NIDDM. Diabetes Care. 1989; 12: 536-539. doi:10.2337/diabetes.42.8.530 PubMed

[17] Harris MI. Racial and ethnic differences in health care access and health outcomes for adults with type 2 diabetes. Diabetes Care. 2001; 24: 454-459. doi:10.2337/diabetes.24.4.454 PubMed

[18] Stevens ML, Fisher JR. Diabetes in North American Indians, U.S.D.O.H.a.H. Services, Editor. National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases. Bethesda: National Institutes of Health, Public Health Service; 1985. p. 72.

[19] Gardner LI Jr, Stern MP, Haffner SM, Gaskill SP, Hazuda HP, Relethford JH, Efier CW. Prevalence of diabetes in Mexican Americans. Relationship to percent of gene pool derived from native American sources. Diabetes. 1984; 33: 86-92. doi:10.2337/diabetes.33.1.86 PubMed

[20] Nelson RG, Bennett PH, Beck GJ, Tan M, Knowler WC, Mitchell WE, Hirschman GH, Myers BD. Diabetic Renal Disease Study Group. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. N Engl J Med. 1996; 335: 1636-1642. doi:10.1056/NEJM199611283352203 PubMed

[21] Kunzelman CL, Knowler WC, Pettitt DJ, Bennett PH. Incidence of proteinuria in type 2 diabetes mellitus in the Pima Indians. Kidney Int. 1989; 35: 681-687. doi:10.1016/0022-3495(89)90392-3 PubMed

[22] Zhang J, Markides KS, Lee DJ. Health status of diabetic Mexican Americans: results from the Hispanic HANES. Ethn Dis. 1991; 1: 273-279. PubMed

[23] Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. JAMA. 2007; 298: 2038-2047. doi:10.1001/jama.298.17.2038 PubMed

[24] Ottimano ME, Black SA, Ray LA, Da X, Markides KS. Correlates of diabetic complications in Mexican-American elders. Ethn Dis. 2002; 12: 252-258. PubMed

[25] Coresh J, Byrd-Holt D, Astor BC, Briggs JP, Eggers PW, Lacher DW, Hostetter TH. Chronic kidney disease awareness, prevalence, and trends among U.S. adults. 1999 to 2000. J Am Soc Nephrol. 2005; 16: 180-188. doi:10.1681/ASN.2004070539 PubMed

[26] Mattis HJ, Hsu CY, Shaykevich S, Curhan G. Use of the albumin/creatinine ratio to detect microalbuminuria: implications of sex and race. J Am Soc Nephrol. 2002; 13: 1034-1039. PubMed

[27] Garza R, Medina R, Basu S, Pugh JA. Predictors of the rate of renal function decline in non-insu-
lin-dependent diabetes mellitus. Am J Nephrol. 1997; 17: 59-67. doi:10.1159/000160973 PubMed

[28] Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cudlitz R, Cushman WC, Gennath S, Grimm RH Jr, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O'Connor P, Pop-Busui R, Schubart U, Simonson TD, Taylor H et al. ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010; 376: 419-430. doi:10.1016/S0140-6736(10)60576-4 PubMed

[29] Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hseuh W, Sowers J; National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000; 36: 646-661. doi:10.1053/ajkd.2000.16725 PubMed

[30] Garg AX, Kilbred BA, Clark WF, Haynes RB, Clase CM. Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. Kidney Int. 2002; 61: 2165-2175. doi:10.1046/j.1523-1755.2002.00356.x PubMed

[31] Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG; DEMAND investigators. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int. 2006; 69: 2057-2063. doi:10.1038/sj.ki.5000377 PubMed

[32] Thomas MC, Maciagga RJ, Jerums G, Weekes A, Moran J, Shaw JE, Atkins RC. Nonalbunimic renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment co-existing with NIDDM (NEFRON) 11). Diabetes Care. 2009; 32: 1497-1502. doi:10.2337/dc08-2186 PubMed

[33] Tonelli M, Jose P, Curhan G, Sacks F, Braunwald E, Pfeffer M. Cholesterol and Recurrent Events (CARE) Trial Investigators. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ. 2006; 332: 1426. doi:10.1136/bmj.38814.566019.2F PubMed

[34] U.S. Renal Data System. Incidence & Prevalence. National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD. 2009. p. 231-240.

[35] U.S. Renal Data System. Incidence & Prevalence, in Atlas of End-Stage Renal Disease in the United States. 2010. National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD. p. 253-266.

[36] Pugh JA, Medina RA, Cornell JC, Basu S. NIDDM is the major cause of diabetic end-stage renal disease. More evidence from a tri-ethnic community. Diabetes. 1995; 44: 1375-1380. doi:10.2337/diabetes.44.12.1375 PubMed

[37] U.S. Renal Data System. Incidence & Prevalence, in Atlas of End-Stage Renal Disease in the United States. National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD. 2006. p. 231-240.

[38] U.S. Renal Data System. A. Incidence of reported ESRD, in Atlas of End-Stage Renal Disease in the United States. 2009, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, p. 429-452.

[39] Murthy BV, Molony DA, Stack AG. Survival advantage of Hispanic patients initiating dialysis in the United States is modified by race. J Am Soc Nephrol. 2005; 16: 782-790. doi:10.1681/ASN.2004080821 PubMed

[40] Pugh JA, Tuley MR, Basu S. Survival among Mexican-Americans, non-Hispanic whites, and African-Americans with end-stage renal disease: the emergence of a minority pattern of increased incidence and prolonged survival. Am J Kidney Dis. 1994; 23: 803-807. PubMed

[41] Frankenfield DL, Rocco MV, Roman SH, McClellan WM. Survival advantage for adult Hispanic hemodialysis patients? Findings from the end-stage renal disease clinical performance measures project. J Am Soc Nephrol. 2003; 14: 180-186. doi:10.1097/01.ASN.0000037400.83593.E6 PubMed

[42] Frankenfield DL, Krishnan SM, Ashby VB, Shearum TH, Rocco MV, Saran R. Differences in mortality among Mexican-American, Puerto Rican, and Cuban-American dialysis patients in the United States. Am J Kidney Dis. 2009; 53: 647-657. doi:10.1053/j.ajkd.2008.10.049 PubMed

[43] Ricks J, Molnar MZ, Kovesdy CP, Koppel JD, Norris KC, Mehrhoa R, Nissenson AR, Arah OA, Greenland S, Kalantar-Zadeh K. Racial and ethnic differences in the association of body mass index and survival in maintenance hemodialysis patients. Am J Kidney Dis. 2011; 58: 574-582. doi:10.1053/j.ajkd.2011.03.023 PubMed

[44] Kalantar-Zadeh K, Koppel JD, Kilpatrick RD, McAllister CJ, Shinaberger CS, Gjertson DW, Greenland S. Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population. Am J Kidney Dis. 2005; 46: 489-500. doi:10.1053/j.ajkd.2005.05.020 PubMed

[45] Pugh JA. Diabetic nephropathy and end-stage renal disease in Mexican Americans. Blood Purif. 1996; 14: 286-292. doi:10.1159/000170275 PubMed

[46] Bresson C, Pociot F. Genetics of diabetic nephropathy in diverse ethnic groups. Contrib Nephrol. 2011; 170: 8-18. doi:10.1016/j.cndnp.2011.01.008 PubMed

[47] Freedman BI, Bostrom M, Daeihagh P, Bowden DW. Genetic factors in diabetic nephropathy. Clin J Am Soc Nephrol. 2007; 2: 1306-1316. doi:10.2215/CJN.02566007 PubMed

[48] Knowler WC, Coresh J, Elston RC, Freedman BI, Iyengar SK, Kimmel PL, Olson JM, Plaatje R, Sedor JR, Seldin MF; Family Investigation of Nephropathy and Diabetes Research Group. The Family Investigation of Nephropathy and Diabetes (FIND): design and methods. J Diabetes Complications. 2005; 19: 1-9. doi:10.1016/j.jdiacomp.2003.12.007 PubMed

[49] Puppala S, Arya R, Thameem F, Arar NH, Bhandari K, Lehman DM, Schneider J, Fowler S, Fau- rook VS, Diego VP, Almasy L, Blangero J, Sten M, Duggirala R, Abbond HE. Genotype by diabetes interaction effects on the detection of linkage of glomerular filtration rate to a region on chromosome 2q in Mexican Americans. Diabetes. 2007; 56: 2818-2828. doi:10.2337/diab06-0984 PubMed
Diabetic kidney disease in Mexican Americans

[50] MacCluer JW, Stern MP, Almasy L, Atwood LA, Blangero J, Comuzzie AG, Dyke B, Haffner SM, Henkel RD, Hisson JE, Kammerer CM, Mahaney MC, Mitchell BD, Rainwater DL, Samollow PB, Sharp RM, Vandenberg JL, Williams JT. Genetics of atherosclerosis risk factors in Mexican Americans. Nutr Rev. 1999; 57: 59-65. doi:10.1111/ j.1753-4877.1999.tb01790.x PubMed

[51] Ezzati TM, Massey JT, Waksberg J, Chu A, Mau- ker KR. Sample design: Third National Health and Nutrition Examination Survey. Vital Health Stat 2. 1992; p.1-35. PubMed

[52] Iyengar SK, Abboud HE, Goddard KA, Saad MF, Adler SG, Arar NH, Bowden DW, Duggirala R, Elston RC, Hanson RL, Ipp E, Kao WH, Kimmel PL, Klag MJ, Knower WC, Meoni LA, Nelson RG, Nicholas SB, Pahl MV, Parekh RS et al. Family Investigation of Nephropathy and Diabetes Research Group. Genome-wide scans for diabetic nephropathy and albuminuria in multietnic popula- tions: the family investigation of nephropathy and diabetes (FIND). Diabetes. 2007; 56: 1577-1585. doi:10.2337/db06-1154 PubMed

[53] Schelling JR, Abboud HE, Nicholas SB, Pahl MV, Sedor JR, Adler SG, Arar NH, Bowden DW, Elston RC, Freedman BI, Goddard KA, Guo X, Hanson RL, Ipp E, Iyengar SK, Jun G, Kao WH, Kasinath BS, Kimmel PL, Klag MJ et al. Family Investigation of Nephropathy and Diabetes Research Group. Genome-wide scan for estimated glomerular filtration rate in multi-ethnic diabetic populations: the family Investigation of Ne- phropathy and Diabetes (FIND). Diabetes. 2008; 57: 235-243. doi:10.2337/db07-0313 PubMed

[54] Bhandari KDR, Kavaliit J, Arya R, Fowler S, Per- gola PE, Plaetke R, Almasy L, O’Connell P, Blangero J, Abboud HE, Stern MP. Genome-wide search for albuminuria susceptibility genes in Mexi- can Americans. Diabetes. 2001; 50: A240-A241.

[55] Lehman DM, Leach RJ, Johnson-Pais T, Hamlington J, Fowler S, Almasy L, Duggirala R, Stern MP, Abboud HE. Evaluation of tight junction protein 1 encoding zona occludens 1 as a candidate gene for albuminuria in a Mexican American population. Exp Clin Endocrinol Diabetes. 2006; 114: 432-437. doi:10.1055/s-2006-924328 PubMed

[56] Thameed F, He X, Vorugunti VS, Nath SD, Fanti P, Blangero J, MacCluer JW, Comuzzie AG, Arar NH, Abboud HE. Evaluation of polymorphisms in paroxonase 2 (PON2) gene and their association with cardiovascular-renal disease risk in Mexican Americans. Kidney Blood Press Res. 2009; 32: 200-204. doi:10.1159/000225943 PubMed

[57] Arar N, Nath S, Thameed F, Bauer R, Vorugunti S, Comuzzie A, Cole S, Blangero J, MacCluer J, Abboud H. Genome-wide scans for microalbum- minuria in Mexican Americans: the San Antonio Family Heart Study. Genet Med. 2007; 9: 80-87. doi:10.1097/GIM.0b013e318030686ec PubMed

[58] Arar NH, Vorugunti VS, Nath SD, Thameed F, Bauer R, Cole SA, Blangero J, MacCluer JW, Comuzzie AG, Abboud HE. A genome-wide search for linkage to chronic kidney disease in a commun- ity-based sample: the SAFSH, Nephrol Dial Transplant. 2008; 23: 3184-3191. doi:10.1093/n dt/gfn215 PubMed

[59] Chu AY, Parekh RS, Astor BC, Coresh J, Berhthier- Schaad Y, Smith MW, Shuldiner AR, Kao WH. As- sociation of APOE polymorphism with chronic kidney disease in a nationally representative sample: a Third National Health and Nutrition Examina- tion Survey (NHANES III) Genetic Study. BMC Med Genet. 2009; 10: 108. doi:10.1186/14 71-2350-10-108 PubMed

[60] Kim S, Abboud HE, Pahl MV, Tayek J, Snyder S, Tamkin J, Alcorn H Jr, Ipp E, Nast CC, Elston RC, Iyengar SK, Adler SG. Examination of association with candidate genes for diabetic nephropathy in a Mexican American population. Clin J Am Soc Nephrol. 2010; 5: 1072-1078. doi:10.2215/CJN.0 6550909 PubMed

[61] Cox NJ, Frigge M, Nicolae DL, Concordan P, Hanis CL, Bell GI, Kong A. Loci on chromosomes 2 (NIDDM1) and 15 interact to increase suscepti- bility to diabetes in Mexican Americans. Nat Genet. 1999; 21: 213-215. doi:10.1038/6602 PubMed

[62] Parra EJ, Below JE, Kritikusa V, Vallsardas A, Bar- ta JL, Cox NJ, Hanis CL, Wucher N, Garcia-Mena J, Hu P, Shriver MD, Kamate J, McKeigue PM, Escobedo J, Cruz M. Diabetes Genetics Replication Meta-analysis and Meta-analysis (DIAGRAM) Consortium. Genome-wide association study of type 2 diabetes in a sample from Mexico City and a meta-analysis of a Mexican-American sample from Starr County, Texas. Diabetologia. 2011; 54: 2038-2046. doi:10.1007/s00125-011-2172-y PubMed

[63] Below JE, Gamazon ER, Morrison JV, Konkash- baev A, Pluzhnikov A, McKeigue PM, Parra EJ, Elhein SC, Hallman DM, Nicolae DL, Bell GI, Cruz M, Cox NJ, Hanis CL. Genome-wide asso- ciation and meta-analysis in populations from Starr County, Texas, and Mexico City identify type 2 diabetes susceptibility loci and enrichment for expression quantitative trait loci in top signals. Diabetologia. 2011; 54: 2047-2055. doi:10.1007/s00125-011-2188-3 PubMed

[64] Hayes MG, Pluzhnikov A, Miyake K, Sun Y, Ng MC, Roe CA, Below JE, Nicolae RJ, Konkashbaev A, Bell GI, Cox NJ, Hanis CL. Identification of type 2 diabetes genes in Mexican Americans through genome-wide association studies. Diabe- tes. 2007; 56: 3033-3044. doi:10.2337/db07-0482 PubMed

[65] del Bosque-Plata L, Aguilar-Salinas CA, Tusi- Luna MT, Ramírez-Jiménez S, Rodríguez-Torres M, Aurón-Gómez M, Ramírez E, Velasco-Pérez ML, Ramírez-Silva A, Gómez-Pérez E, Hanis CL, Tsuchiya T, Yoshitaki I, Cox NJ, Bell GI. Association of the calpain-10 gene with type 2 diabetes mellitus in a Mexican population. Mol Genet Metab. 2004; 81: 122-126. doi:10.1016/j.mgen.2003.10.005 PubMed

[66] Hanis CL, Boerwinkle E, Chakraborty R, Ellis- worth DL, Concordan P, Stirling B, Morrison VA, Wapelhorst B, Spielman RS, Gogolin-Evens KJ, Shepard JM, Williams SR, Risch N, Hinds D, Iwasa- niki N, Ogata M, Omori Y, Petzold C, Rietzch H, Schröder HE et al. A genome-wide search for hu- man non-insulin-dependent (type 2) diabetes genes reveals a major susceptibility locus on chro- mosome 2. Nat Genet. 1996; 13: 161-166. doi:10. 1038/ng0996-161 PubMed

[67] Wang J, Geiss LS, Cheng YJ, Imperatore G, Say- dah SH, James C, Gregg EW. Long-term and re- cent progress in blood pressure levels among U.S.
adults with diagnosed diabetes, 1988-2008. Diabetes Care. 2011; 34: 1579-1581. doi:10.2337/doi-11-0178 PubMed

[68] Ostchega Y, Yoon SS, Hughes J et al. Hypertension awareness, treatment, and control--continued disparities in adults: United States, 2005-2006. NCHS Data Brief, 2008(3). p. 1-8.

[69] Hoffner SM, Mitchell BD, Stern MP, Hazuda HP. Macrovascular complications in Mexican Americans with type II diabetes. Diabetes Care. 1991; 14: 665-671. doi:10.2337/diabetes.39.11.1430 PubMed

[70] Hoffner SM, Morales PA, Gruber MK, Hazuda HP. Stern MP. Cardiovascular risk factors in non-insulin-dependent diabetic subjects with microalbuminuria. Arterioscler Thromb. 1993; 13: 205-210. doi:10.1161/01.ATV.13.2.205 PubMed

[71] Cowie CC, Harris MI. Physical and Metabolic Characteristics of Persons with Diabetes, U.S.D.o.H.a.H. Services, Editor. The National Diabetes Information Clearinghouse (NDIC); 1995. p. 117-164.

[72] Geiss LS, Rolka DB, Engelgu MM. Elevated blood pressure among U.S. adults with diabetes, 1988-1994. Am J Prev Med. 2002; 22: 42-48. doi:10.1016/S0749-3797(01)00399-3 PubMed

[73] Saad MF, Lilioja S, Nyomba BI, Castillo C, Ferraro R, De Gregorio M, Ravassini K, Knowler WC, Bennett PH, Howard BV, Bogardus C. Racial differences in the relation between blood pressure and insulin resistance. N Engl J Med. 1991; 324: 733-739. doi:10.1056/NEJM199103143241105 PubMed

[74] Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH. Insulin and hypertension. Relationship to obesity and glucose intolerance in Pima Indians. Diabetes. 1990; 39: 1430-1435. doi:10.2337/diabetes.39.11.1430 PubMed

[75] Satish S, Markides KS, Zhang D, Goodwin JS. Factors influencing unawareness of hypertension among older Mexican Americans. Prev Med. 1997; 26: 645-650. doi:10.1006/pmed.1997.0232 PubMed

[76] Satish S, Stroup-Benham CA, Espino DF, Markides KS, Goodwin JS. Undertreatment of hypertension in older Mexican Americans. J Am Geriatr Soc. 1998; 46: 405-410. PubMed

[77] Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labardee D. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995; 25: 305-313. PubMed

[78] Fischer MJ, Go AS, Loria CM, Ackerson L, Cohan J, Kusek JW, Mercado A, Ojo A, Ricardo AC, Rosen LK, Tao K, Xie D, Feldman HI, Lash JP; CRIC and H-CRIC Study Groups. CKD in Hispanics: Baseline characteristics from the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic-CRIC Studies. Am J Kidney Dis. 2011; 58: 214-227. doi:10.1053/j.ajkd.2011.05.010 PubMed

[79] Strippoli GF, Bonnati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2006; CD006257. PubMed

[80] Ravera M, Ratto E, Vettoretti S, Parodi D, Deffarari G. Prevention and treatment of diabetic nephropathy: the program for irbesartan mortality and morbidity evaluation. J Am Soc Nephrol. 2005; 16 (Suppl 1): S48-S52. doi:10.1681/ASN.2004110957 PubMed

[81] Barnett AH. Preventing renal complications in diabetic patients: the diabetics exposed to telmisartan and enalapril (DETAIL) study. Acta Diabetol. 2005; 42 (Suppl 1): S42-S49. doi:10.1007/s00592-005-0180-4 PubMed

[82] Raggi MA, Kuo YF, Salazar JA, Satish S, Goodwin JS. Ethnic differences in antihypertensive medication use in the elderly. Ann Pharmacother. 2004; 38: 209-214. doi:10.1345/aph.1D224 PubMed

[83] Kramer H, Han C, Post W, Goff D, Diez-Roux A, Cooper R, Jinagouda S, Shea S. Racial/ethnic differences in hypertension and hypertension treatment and control in the multi-ethnic study of atherosclerosis (MESA). Am J Hypertens. 2004; 17: 963-970. doi:10.1016/j.amjhyp.2004.06.001 PubMed

[84] Gu Q, Paulose-Ram R, Dillon C, Burt V. Antihypertensive medication use among US adults with hypertension. Circulation. 2006; 113: 213-221. doi:10.1161/CIRCULATIONAHA.105.542290 PubMed

[85] de Zeeuw D, Ramjit D, Zhang Z, Ribeiro AV, Kurokawa K, Lash JP, Chan J, Remuzzi G, Brenner BM, Shabina S. Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAAL. Kidney Int. 2006; 69: 1675-1682. doi:10.1038/sj.ki.500326 PubMed

[86] Coleman CI, Baker WL, Kluger J et al. Comparative effectiveness of angiotensin converting enzyme inhibitors or angiotensin II receptor blockers added to standard medical therapy for treating stable ischemic heart disease. University of Connecticut/Hartford Hospital Evidence-based Practice Center. 2009.

[87] Kawazu S, Tomono S, Shimizu M, Kato N, Ohno T, Ishii C, Murata K, Watanabe T, Negishi K, Suzuki M, Takahashi M, Ishii J. The relationship between early diabetic nephropathy and control of plasma glucose in non-insulin-dependent diabetes mellitus. The effect of glycemic control on the development and progression of diabetic nephropathy: an 8-year follow-up study. J Diabetes Complications. 1994; 8: 13-17. doi:10.1016/1056-8727(94)90005-1 PubMed

[88] Levin SR, Colburn JW, Abhara C, Henderson WG, Colwell JA, Emanuele NV, Nattall FQ, Sawin CT, Comstock JP, Silberk CK. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care. 2000; 23: 1478-1485. doi:10.2337/diabetes.23.10.1478 PubMed

[89] The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329: 977-986. doi:10.1056/NEJM199309303291401 PubMed

[90] Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Di-
Diabetic kidney disease in Mexican Americans

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-853. doi:10.1016/S0140-6736(98)07071-9 PubMed

Gaede P, Vedel P, Larsen N, Jensen GT, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003; 348: 383-393. doi:10.1056/NEJMoa021778 PubMed

Harris MI. Epidemiological correlates of NIDDM in Hispanics, whites, and blacks in the U.S. population. Diabetes Care. 1991; 14: 639-648. doi:10.2337/diabetes.14.7.639

West SK, Klein R, Rodriguez J, Muñoz B, Bromman AT, Sanchez R, Snyder R. Projecto VER. Diabetes and diabetic retinopathy in a Mexican-American population: Projecto VER. Diabetes Care. 2001; 24: 1204-1209. doi:10.2337/diacare.24.7.1204 PubMed

Brown AF, Gerzoff RB, Karter AJ, Gregg E, Safford M, Watzfelder B, Beckles GL, Brusuelas R, Mangione CM. TRIAD Study Group. Health behaviors and quality of care among Latinos with diabetes in managed care. Am J Public Health. 2003; 93: 1694-1698. doi:10.2105/AJPH.93.10.1694 PubMed

Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care. 1999; 22: 403-408. doi:10.2337/diacare.24.7.1204 PubMed

Hertz RP, Unger AN, Ferrario CM. Diabetes, hypertension, and dyslipidemia in Mexican Americans and non-Hispanic whites. Am J Prev Med. 2006; 30: 103-110. doi:10.1016/j.amepre.2005.10.015 PubMed

Bonds DE, Zaccaro DJ, Karter AJ, Selby JJ, Saad M, Goff DC Jr. Ethnic and racial differences in diabetes care: The Insulin Resistance Atherosclerosis Study. Diabetes Care. 2003; 26: 1040-1046. doi:10.2337/diacare.26.4.1040 PubMed

Mainous AG III, Diaz VA, Koopman RJ, Everett CJ. Quality of care for Hispanic adults with diabetes. Fam Med. 2007; 39: 351-356. PubMed

Saaadine JB, Engelgau MM, Beckles GL, Gregg EW, Thompson TJ, Narayan KM. A diabetes report card for the United States: quality of care in the 1990s. Ann Intern Med. 2002; 136: 565-574. PubMed

Saaadine JB, Cadwell B, Gregg EW, Engelgau MM, Vinicor F, Imperatore G, Narayan KM. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med. 2006; 144: 465-474. PubMed

Ravidi M, Brash D, Ravidi-Safaran D, Levy Z, Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med. 1998; 158: 998-1004. doi:10.1001/archinte.158.9.998 PubMed

Sharma MD, Pavlik VN. Dyslipidaemia in African Americans, Hispanics and whites with type 2 diabetes mellitus and hypertension. Diabetes Obes Metab. 2001; 3: 41-45. doi:10.1046/j.1463-1326.2001.00113.x PubMed

Goff DC Jr, Bertoni AG, Kramer H, Bonds D, Blumenthal RS, Tsai MY, Psaty BM. Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium. Circulation. 2006; 113: 647-656. doi:10.1161/CIRCULATIONAHA.105.525737 PubMed

Gall MA, Hougaard P, Borch-Johnsen K, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ. 1997; 314: 783-788. doi:10.1136/bmj.314.7083.783 PubMed

Kramer H, Reboussin D, Bertoni AG, Marcovina S, Lipkin E, Greenway FL, III, Brancati FL. Look AHEAD Research Group. Obesity and albuminuria among adults with type 2 diabetes: the Look AHEAD (Action for Health in Diabetes) Study. Diabetes Care. 2009; 32: 851-853. doi:10.2337/dc08-2059 PubMed

Afshin Farrokhnia, F, Wilt TJ, Duval S et al. Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts. Nephrol Dial Transplant. 2009.

Cueto-Manzano AM, Cortes-Sanabria L, Martinez-Ramirez HR, Rojas-Campos E, Barragan G, Alfaoro G, Flores J, Anaya M, Canales-Munoz JL. Detection of early nephropathy in Mexican patients with type 2 diabetes mellitus. Kidney Int Suppl. 2005; 68 (s97): S40-S45. doi:10.1111/j.1523-1755.2005.00707.x PubMed

Haffner SM, Mitchell BD, Stern MP, Haza H, Patterson JK. Public health significance of upper body adiposity for non-insulin dependent diabetes mellitus in Mexican Americans. Int J Obes Relat Metab Disord. 1992; 16: 177-184. PubMed

Wei M, Gaskill SP, Haffner SM, Stern MP. Waist circumference as the best predictor of noninsulin dependent diabetes mellitus (NIDDM) compared to body mass index, waist/hip ratio and other anthropometric measurements in Mexican Americans -- a 7-year prospective study. Obes Res. 1997; 5: 16-23. PubMed

Monterrosa AE, Haffner SM, Stern MP, Haza H. Sex difference in lifestyle factors predictive of diabetes in Mexican-Americans. Diabetes Care. 1995; 18: 448-456. doi:10.2337/diacare.18.4.448 PubMed

Haffner SM. Hyperinsulinemia as a possible etiology for the high prevalence of non insulin dependent diabetes mellitus in Mexican Americans. Diabete Metab. 1987; 13: 337-344. PubMed

Haffner SM, Stern MP, Haza H, Pugh JA, Patterson JK. Hyperinsulinemia in a population at high risk for non-insulin-dependent diabetes mellitus. N Engl J Med. 1986; 315: 220-224. doi:10.1056/NEJM198607243150403 PubMed

Haffner SM, Miettinen H, Stern MP. Insulin secretion and resistance in non-diabetic Mexican Americans and non-Hispanic whites with a parental history of diabetes. J Clin Endocrinol Metab. 1996; 81: 1846-1851. doi:10.1210/jc.81.5.1846 PubMed

Galli G, Ferrannini E, Stern M, Haffner S, DeFronzo RA. The metabolic profile of NIDDM is...
fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents. Diabetes. 1992; 41: 1575-1586. doi:10.2337/dbiabetes.41.12.1575 PubMed

[116] Belfiore F, Fannello S. Reduced insulin sensitivity in Mexican-Americans from San Antonio with elevated incidence of type 2 diabetes compared with Mexicans from Mexico City. Diabetes Care. 2002; 25: 937-938., author reply 938-939. doi:10.2337/diabetes.25.5.937-a PubMed

[117] Burke JP, Williams K, Hoffner SM, Villalpando CG, Stern MP. Elevated incidence of type 2 diabetes in San Antonio, Texas, compared with that of Mexico City, Mexico. Diabetes Care. 2001; 24: 1573-1578. doi:10.2337/diabetes.24.9.1573 PubMed

[118] Finkenstein J, Joshi A, Hise MK. Association of physical activity and renal function in subjects with and without metabolic syndrome: a review of the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis. 2006; 48: 372-382. doi:10.1053/j.ajkd.2006.05.013 PubMed

[119] Kuo YF, Raji MA, Markides KS, Ray LA, Espino DV, Goodwin JS. Inconsistent use of diabetes medications, diabetes complications, and mortality in older Mexican Americans over a 7-year period: data from the Hispanic established population for the epidemiologic study of the elderly. Diabetes Care. 2003; 26: 3054-3060. doi:10.2337/diabetes.26.11.3054 PubMed

[120] Johnson L, Strich H, Taylor A, Timmermann B, Muldoon D, Teufel-Shone N, Drummond R, Woolery R, Pereira E, Martinez A. Use of herbal remedies by diabetic Hispanic women in the southwestern United States. Phytother Res. 2006; 20: 250-255. doi:10.1002/ptr.1820 PubMed

[121] Ortiz BI, Shields KM, Clauson KA, Clay PG. Complementary and alternative medicine use among Hispanics in the United States. Ann Pharmacother. 2007; 41: 994-1004. doi:10.1345/aph.1H600 PubMed

[122] Hunt LM, Arar NH, Akana LL. Herbs, prayer, and insulin. Use of medical and alternative treatments by a group of Mexican American diabetes patients. J Fam Pract. 2000; 49: 216-223. PubMed

[123] Noel PH, Pugh JA, Larne AC, Marsh G. The use of traditional plant medicines for non-insulin-dependent diabetes mellitus in South Texas. Phytother Res. 1997; 11: 512-517. doi:10.1002/(SICI)1099-1573(199711)11:7<512::AID-PTI1493.0.CO;2-H

[124] Poss JE, Jezewski MA, Staat AG. Home remedies for type 2 diabetes used by Mexican Americans in El Paso, Texas. Clin Nurs Res. 2003; 12: 304-323. doi:10.1177/1054773803256872 PubMed

[125] Bell RA, Suerken CK, Grzywacz JG, Lang W, Quandt SA, Arcury TA. Complementary and alternative medicine use among adults with diabetes in the United States. Altern Ther Health Med. 2006; 12: 16-22. PubMed

[126] Garrow D, Egede LE. National patterns and correlates of complementary and alternative medicine use in adults with diabetes. J Altern Complement Med. 2006; 12: 895-902. doi:10.1089/acm.2006.12.895 PubMed

[127] Egede LE, Ye X, Zheng D, Silverstein MD. The prevalence and pattern of complementary and alternative medicine use in individuals with diabetes. Diabetes Care. 2002; 25: 324-329. doi:10.2337/diabetes.25.2.324 PubMed

[128] Markell MS. Potential benefits of complementary medicine modalities in patients with chronic kidney disease. Adv Chronic Kidney Dis. 2005; 12: 292-299. doi:10.1016/j.ackd.2005.03.004 PubMed

[129] Drige W. Free radicals in the physiological control of cell function. Physiol Rev. 2002; 82: 47-95. PubMed

[130] West IC. Radicals and oxidative stress in diabetes. Diabet Med. 2000; 17: 171-180. doi:10.1046/j.1464-5491.2000.00259.x PubMed

[131] Rösen P, Nawroth PP, King G, Möller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabet Med Metab Res Rev. 2001; 17: 189-212. PubMed doi:10.1002/dmrr.196

[132] Evans JL, Maddux BA, Goldfine ID. The molecular basis for oxidative stress-induced insulin resistance. Antioxid Redox Signal. 2005; 7: 1040-1052. doi:10.1089/ars.2005.7.1040 PubMed

[133] Parving HH, Mauer M, Ritz E. Diabetic Nephropathy, in Brenner & Rector’s The Kidney, B.M. Brenner and S.A. Levine, Editors. Saunders Elsevier: Philadelphia, PA; 2008. p. 1265-1298.

[134] Stoddard P, He G, Vijayaraghavan M, Schilling D. Disparities in undiagnosed diabetes among United States-Mexico border populations. Rev Panam Salud Publica. 2010; 28: 198-206. doi:10.1590/S1020-4989201000090010 PubMed

[135] Lanting IC, Joung IM, Mackenbach JP, Lambert SW, Bootsma AH. Ethnic differences in mortality, end-stage complications, and quality of care among diabetic patients: a review. Diabetes Care. 2005; 28: 2280-2288. doi:10.2337/diabetes.28.9.2280 PubMed

[136] Cowie CC, Eberhardts MS. Sociodemographic Characteristics of Persons with Diabetes, U.S.D.O.Ha.H. Services, Editor. The National Diabetes Information Clearinghouse (NDIC); 1995. p. 85-116.

[137] Merriam PA, Tellez TL, Rosal MC, Olendzki BC, Markes M, Perez-Stable EJ. Methodology of a diabetes prevention translational research project utilizing a community-academic partnership for implementation in an underserved Latino community. BMC Med Res Methodol. 2009; 9: 20. doi:10.1186/1471-2288-9-20 PubMed

[138] Teufel-Shone NI, Drummond R, Rawiel U. Developing and adapting a family-based diabetes program at the U.S.-Mexico border. Prev Chronic Dis. 2005; 2: A20 PubMed

[139] Correa-Rotter R, Gonzalez-Michaca L. Early detection and prevention of diabetic nephropathy: a challenge calling for mandatory action for Mexico and the developing world. Kidney Int Suppl. 2005; 68 (s98): S69-S75. doi:10.1111/j.1525-1755.2005.00413.x PubMed

[140] Thameem F, Puppala S, He X et al. Evaluation of gremlin 1 (GREM1) as a candidate susceptibility gene for albimunria-related traits in Mexican Americans with type 2 diabetes mellitus. Metabolism. 2009; 58: 1496-1502.